When it comes to analyzing Becton Dickinson net worth, its financial performance plays a crucial role.
As a global medical technology leader, Becton Dickinson continues to grow and dominate its industry.
In this article, I’ll dive deep into how BD generates revenue, manage assets, and stays competitive in 2024. Here’s what you need to know!
Quick Facts
| FACT | DETAIL |
|---|---|
| Name | BD |
| Full Name | Becton, Dickinson and Company |
| Website | www.bd.com |
| Industry | Medical Technology |
| Traded as | NYSE: BDX |
| ISIN | US0758871091 |
| Founded | 1897 |
| Founders | Maxwell Becton, Fairleigh Dickinson |
| Country/Territory | United States |
| Headquarters | Franklin Lakes, NJ, USA |
| Chief Executive Officer | Tom Polen |
| Number of Employees | 70,000+ |
| Market Cap | $68.99 billion (October 2024) |
| Total Assets | $55.58 billion (June 2024) |
| Total Equity | $25.87 billion (June 2024) |
| Revenue | $14.74 billion (Nine months, FY 2024) |
| Net Income | $487 million (Q3 2024) |
What is the Net Worth or Market Cap Of Becton Dickinson in 2024?
As of October 2024, Becton Dickinson boasts a market cap of $68.99 billion, placing it among the largest medical technology companies in the world.
This value showcases the company’s impressive financial growth. When compared to other major players, BD’s size and financial health are evident. While it’s not the top richest company globally, it competes fiercely in its sector.
Here are some companies related to BD:
- Edwards Lifesciences
- Medtronic
- Baxter International
- Stryker Corporation
- Johnson & Johnson
If you’re curious to learn more about other companies in this category, check out our article on the biggest healthcare companies by visiting this page.
Becton Dickinson Revenue and Financial Performance Overview
How BD Generates Revenue Across Its Segments
BD generates substantial revenue across its three main segments: BD Medical, BD Life Sciences, and BD Interventional. In Q3 FY 2024, the total revenue stood at $4.99 billion, with BD Medical being the largest contributor at $2.56 billion.
This segment benefits from strong performances in Medication Delivery Solutions and Medication Management Solutions, which grew by 6.8% and 15.9%, respectively.
The BD Life Sciences segment contributed $1.26 billion, driven by Integrated Diagnostic Solutions and Specimen Management.
Meanwhile, BD Interventional reported $1.24 billion in revenue, with growth in surgery and Urology and Critical Care. These segments are pillars of BD’s overall financial success.
Financial Performance Over Recent Years
Over the past several years, Becton Dickinson has consistently grown, with its total revenue for the first nine months of FY 2024 reaching $14.74 billion, representing a 3.2% growth year-over-year.
Notably, free cash flow increased by 106% to $2.24 billion, demonstrating strong financial management and operating efficiency.
This financial growth highlights BD’s ability to adapt and thrive in a competitive market.
By continuously investing in research and development, the company maintains its leadership in medical technology innovation.
Key Acquisitions and Their Revenue Impact
One of the notable acquisitions in 2024 was the $4.2 billion purchase of Edwards Lifesciences’ Critical Care Product Group.
This acquisition significantly enhanced BD’s portfolio, particularly in smart connected care solutions and AI-based monitoring technologies.
The integration of Edwards Lifesciences’ assets into BD’s operations has had a positive impact on revenue, contributing to BD’s leading position in the market.
Operating Income and Profit Margins
Becton Dickinson has demonstrated strong margin performance, with operating income in Q3 FY 2024 reaching $602 million, reflecting a 9.7% increase compared to the previous year.
The company’s ability to control costs is reflected in a 3.4% reduction in the cost of products sold.
Furthermore, adjusted diluted earnings per share (EPS) grew by 18.2% in the same period, reinforcing BD’s focus on profitability.
Asset and Liability Management
BD’s total assets as of June 30, 2024, stood at $55.58 billion, while total equity was $25.87 billion.
The company has carefully managed its liabilities, including $18.13 billion in long-term debt.
BD’s strong financial position allows it to continue investing in innovations and acquisitions while maintaining a healthy balance sheet.
The company’s liquidity has also significantly improved, with cash and equivalents reaching $4.46 billion by mid-2024, compared to $1.42 billion in 2023.
These metrics indicate a robust financial framework capable of supporting its strategic goals.
BD’s Earnings Outlook and Forecasts
Looking ahead, BD has provided guidance for FY 2024, forecasting adjusted revenues of $20.1 billion to $20.2 billion.
The company also projects adjusted diluted EPS of $13.05 to $13.15, up from its previous estimate.
These forecasts reflect confidence in BD’s organic revenue growth of 5.0% to 5.25% and its ability to deliver on its long-term objectives.
Revenue Distribution Across Global Markets
BD’s revenue is also geographically diverse. In Q3 FY 2024, the company generated $2.89 billion from the United States, an increase of 4.3% from the previous year.
Internationally, revenue was $2.10 billion, showing slight growth despite challenges in some regions.
This global distribution highlights BD’s resilience and its ability to generate consistent revenue across different markets.
FAQs About Becton Dickinson
How does BD generate its revenue?
It generates revenue through its three primary segments: BD Medical, BD Life Sciences, and BD Interventional.
What are the main business segments of BD?
It operates in three main segments: BD Medical, BD Life Sciences, and BD Interventional. Each contributes significantly to the company’s overall revenue.
How much revenue did BD generate in Q3 2024?
In Q3 2024, BD generated $4.99 billion in revenue. The company’s strong performance in BD Medical and BD Interventional drove this growth.
What are BD’s revenue projections for FY 2024?
BD has projected adjusted revenues of approximately $20.1 billion to $20.2 billion for FY 2024, with expected organic revenue growth of 5.0% to 5.25%.
How has BD improved its free cash flow?
BD’s free cash flow saw a significant improvement in FY 2024, increasing by 106% to $2.24 billion due to higher cash from continuing operations and effective cost management.
Conclusion
In conclusion, Becton Dickinson’s financial journey in 2024 showcases robust growth across its business segments, supported by strategic acquisitions and innovative product launches.
For more updates and in-depth analyses, feel free to visit Ando Money, share your thoughts, or explore further financial insights.
